Sunday, July 20, 2025
  • Login
No Result
View All Result
ForexTV
  • News
    • Top Corporate News
    • Lifestyle
    • Technology
    • Financial Markets News
  • Small Business
    • Digital Marketing Blog
    • Small Business Best Practices
    • Small Business Strategy
      • Sales Strategies
      • Marketing Strategies
  • Business Finance
    • Small Business-Lending Trends
    • Debt Service Coverage Ratio (DSCR)
    • Business Credit
      • Business Credit Blog
      • Business Loans
      • Merchant Cash Advances
      • Business Line of Credit
      • What is Alternative Business Lending?
    • Resources
      • Debt Service Coverage Ratio (DSCR) Calculator
  • Currency Focus
    • Crypto Focus
      • Bitcoin (BTC)
      • Ethereum (ETH)
      • Tether
      • BNB
      • Cardano (Ada)
      • Ripple (XRP)
      • Solana (SOL)
      • Dogecoin (DOGE)
      • Polkadot (DOT)
      • Tron (TRX)
      • Shiba Inu (SHIB)
      • Litecoin (LTC)
    • EURO (EUR)
    • Japanese Yen (JPY)
    • Great British Pound (GBP)
    • Swiss Franc (CHF)
    • New Zealand Dollar (NZD)
    • Canadian Dollar (CAD)
    • Australian Dollar (AUD)
  • Resources
    • Economic Calendar
    • Trader Education
      • Candlestick Pattern Intro
    • Live Forex Rates/Charts
      • Live Rates
      • Live Charts
    • Forex Trader Tools
      • Pivot Point Calculator
      • Currency Converter
      • Global Statistic Resources
    • Trading Terms
      • Forex Glossary
      • Glossary of Retirement Industry Terms
    • CPI Tools
      • CPI Inflation Calculator
      • CPI Average Price Calculator
  • Marketing Services
    • Digital Marketing Services
    • Digital Marketing Consulting
    • Search Engine Optimization (SEO)
    • Online Content Marketing
    • Digital Marketing Blog
    • Inbound Marketing Services
    • Email Marketing
    • Digital Marketing Rates
  • News
    • Top Corporate News
    • Lifestyle
    • Technology
    • Financial Markets News
  • Small Business
    • Digital Marketing Blog
    • Small Business Best Practices
    • Small Business Strategy
      • Sales Strategies
      • Marketing Strategies
  • Business Finance
    • Small Business-Lending Trends
    • Debt Service Coverage Ratio (DSCR)
    • Business Credit
      • Business Credit Blog
      • Business Loans
      • Merchant Cash Advances
      • Business Line of Credit
      • What is Alternative Business Lending?
    • Resources
      • Debt Service Coverage Ratio (DSCR) Calculator
  • Currency Focus
    • Crypto Focus
      • Bitcoin (BTC)
      • Ethereum (ETH)
      • Tether
      • BNB
      • Cardano (Ada)
      • Ripple (XRP)
      • Solana (SOL)
      • Dogecoin (DOGE)
      • Polkadot (DOT)
      • Tron (TRX)
      • Shiba Inu (SHIB)
      • Litecoin (LTC)
    • EURO (EUR)
    • Japanese Yen (JPY)
    • Great British Pound (GBP)
    • Swiss Franc (CHF)
    • New Zealand Dollar (NZD)
    • Canadian Dollar (CAD)
    • Australian Dollar (AUD)
  • Resources
    • Economic Calendar
    • Trader Education
      • Candlestick Pattern Intro
    • Live Forex Rates/Charts
      • Live Rates
      • Live Charts
    • Forex Trader Tools
      • Pivot Point Calculator
      • Currency Converter
      • Global Statistic Resources
    • Trading Terms
      • Forex Glossary
      • Glossary of Retirement Industry Terms
    • CPI Tools
      • CPI Inflation Calculator
      • CPI Average Price Calculator
  • Marketing Services
    • Digital Marketing Services
    • Digital Marketing Consulting
    • Search Engine Optimization (SEO)
    • Online Content Marketing
    • Digital Marketing Blog
    • Inbound Marketing Services
    • Email Marketing
    • Digital Marketing Rates
No Result
View All Result
ForexTV
No Result
View All Result
ADVERTISEMENTS
club Felene

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

by GlobeNewswire
March 31, 2025
in Top News
Reading Time: 18 mins read
  • The PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is on track to report topline data in Q2 2025
  • VIKTORIA-2 Phase 3 remains on track to enroll its first patient in Q2 2025
  • Presented encouraging preliminary overall survival data from the Phase 1b study evaluating gedatolisib in combination with palbociclib and endocrine therapy at the 2024 SABCS
  • Approximately $235.1 million in cash, cash equivalents and short-term investments at end of Q4 2024 expected to fund current clinical development program activities through 2026
  • Management to host webcast and conference call today, March 31, 2025, at 4:30 p.m. ET

MINNEAPOLIS, March 31, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter ended December 31, 2024 and other recent business developments.

“We expect 2025 to be a transformational year for Celcuity as we anticipate reporting several clinical data readouts, including primary analysis for the PIK3CA wild-type cohort of the VIKTORIA-1 trial. We expect to share topline data in Q2 2025,” said Brian Sullivan, CEO and co-founder of Celcuity. “In addition, we anticipate reporting topline data for the Phase 1b/2 trial in metastatic castration resistant prostate cancer in late Q2 2025, and topline data for the PIK3CA mutant-type cohort of the VIKTORIA-1 trial in Q4 2025. We also remain on track to enroll the first patient for our VIKTORIA-2 Phase 3 trial in Q2 2025.”

Fourth Quarter 2024 Business Highlights and Other Recent Developments

  • The VIKTORIA-1 Phase 3 clinical trial evaluating gedatolisib in combination with fulvestrant with and without palbociclib in adults with HR+, HER2- advanced breast cancer who have received prior treatment with a CDK4/6 inhibitor is 100% enrolled for the PIK3CA wild-type cohort. We expect to provide topline data in Q2 2025.
    • Enrollment for the PIK3CA mutant cohort remains on track and topline data is expected in Q4 of 2025.
  • The VIKTORIA-2 Phase 3 open-label randomized study evaluating the efficacy and safety of gedatolisib in combination with fulvestrant plus a CDK4/6 inhibitor, either ribociclib or palbociclib, in comparison to fulvestrant plus a CDK4/6 inhibitor as a first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy resistant remains on track to enroll its first patient in Q2 2025.
    • A safety run-in study preceding the initiation of the Phase 3 portion of the study will be conducted in 12-36 participants to assess the safety profile of gedatolisib in combination with ribociclib and fulvestrant.
    • Site selection activities are completed. We expect to activate approximately 200 sites across North America, Europe, Latin America, and Asia-Pacific.
    • The Phase 3 portion of the study is expected to enroll approximately 638 patients.
  • The Phase 1b/2 clinical trial, evaluating gedatolisib in combination with darolutamide for the treatment of patients with metastatic castration resistant prostate cancer (“mCRPC”), is ongoing and remains on track to report preliminary data in late Q2 2025.
    • The study is expected to enroll up to 54 patients with mCRPC whose disease progressed while on or after treatment with an androgen receptor signaling inhibitor.
  • In December 2024, Celcuity presented overall survival data from a Phase 1b trial, which evaluated gedatolisib in combination with palbociclib and either letrozole or fulvestrant, in patients with HR+, HER2- advanced or metastatic breast cancer during a poster session at the 2024 San Antonio Breast Cancer Symposium (SABCS). Median overall survival was 77.3 months among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting and 33.9 months among patients previously treated with a CDK4/6 inhibitor.
    • Results compare favorably to published data for currently available first- or second-line standard-of-care treatment regimens for patients with HR+, HER2- advanced breast cancer and highlight the promising clinical development strategy of simultaneously inhibiting the ER, CDK4/6, and PAM (PI3K/AKT/mTOR) signaling pathways.

Fourth Quarter and Full Year 2024 Financial Results

Unless otherwise stated, all comparisons are for the fourth quarter and full year ended December 31, 2024, compared to the fourth quarter and full year ended December 31, 2023.

Total operating expenses were $36.4 million for the fourth quarter of 2024, compared to $19.7 million for the fourth quarter of 2023. Operating expenses for the full year 2024 were $113.3 million, compared to $66.2 million for the full year 2023.

Research and development (“R&D”) expenses were $33.5 million for the fourth quarter of 2024, compared to $18.1 million for the prior-year period. Of the approximately $15.4 million increase in R&D expenses, $9.9 million primarily related to costs supporting ongoing activities for the VIKTORIA-1 Phase 3 trial and the CELC-G-201 Phase 1b/2 trial, along with the commencement of the VIKTORIA-2 Phase 3 trial. The remaining $5.5 million primarily relates to increased employee and consulting expenses.

R&D expenses for the full year 2024 were $104.2 million, compared to $60.6 million for the prior year. Of the approximately $43.6 million increase in R&D expenses, $30.7 million was related to costs supporting ongoing activities for the VIKTORIA-1 Phase 3 trial and the CELC-G-201 Phase 1b/2 clinical trial, along with the commencement of the VIKTORIA-2 Phase 3 trial. The remaining $12.9 million increase in R&D expenses was primarily related to increased employee and consulting expenses.

General and administrative (“G&A”) expenses were $3.0 million for the fourth quarter of 2024, compared to $1.6 million for the prior year period. Of the approximately $1.4 million increase, $1.1 million was related to increased employee-related expenses, and $0.3 million was related to professional fees, expanding infrastructure costs and other administrative expenses.

G&A expenses for the full year 2024 were $9.1 million, compared to $5.6 million for the prior year. Of the approximately $3.4 million increase in G&A expenses, $2.6 million was related to increased employee-related expenses, and $0.8 million was related to professional fees, expanding infrastructure costs, and other administrative expenses.

Net loss for the fourth quarter of 2024 was $36.7 million, or $0.85 loss per share, compared to a net loss of $18.8 million, or $0.65 loss per share, for the fourth quarter of 2023. Net loss for the full year 2024 was $111.8 million, or $2.83 loss per share, compared to a net loss of $63.8 million, or $2.69 loss per share, in 2023. Non-GAAP adjusted net loss for the fourth quarter of 2024 was $32.3 million, or $0.75 loss per share, compared to non-GAAP adjusted net loss of $17.6 million, or $0.61 loss per share, for the fourth quarter of 2023. Non-GAAP adjusted net loss for the full year 2024 was $101.9 million, or $2.58 loss per share, compared to non-GAAP adjusted net loss of $57.8 million, or $2.44 loss per share, for 2023. Non-GAAP adjusted net loss excludes stock-based compensation expense, non-cash interest expense, and non-cash interest income. Because these items have no impact on Celcuity’s cash position, management believes non-GAAP adjusted net loss better enables Celcuity to focus on cash used in operations. For a reconciliation of financial measures calculated in accordance with generally accepted accounting principles in the United States (“GAAP”) to non-GAAP financial measures, please see the financial tables at the end of this press release.

Net cash used in operating activities for the fourth quarter of 2024 was $27.8 million, compared to $18.5 million for the fourth quarter of 2023. Net cash used in operating activities for the full year 2024 was $83.5 million, compared to $53.8 million for the full year 2023. Cash, cash equivalents and short-term investments were approximately $235.1 million at the end of fiscal year 2024 and are expected to fund current clinical development program activities through 2026.

Webcast and Conference Call Information

The Celcuity management team will host a webcast/conference call at 4:30 p.m. ET today to discuss the fourth quarter and full year 2024 financial results and provide a corporate update. To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1704367&tp_key=f99d4186f3. A replay of the webcast will be available on the Celcuity website following the live event.

About Celcuity

Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company’s lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+, HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov . A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently recruiting patients. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com . Follow us on LinkedIn and Twitter .

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” including, but not limited to, the design of our clinical trials; the timing of initiating and enrolling patients in, and receiving results and data from, our clinical trials; the costs and expected results from any ongoing or planned clinical trials; the market opportunity for gedatolisib; revenue expectations; our strategy, marketing and commercialization plans, including the benefits of strategic decisions regarding studies and trials; other expectations with respect to Celcuity’s lead product candidate, gedatolisib, and its CELsignia platform; our anticipated use of cash; and the strength of our balance sheet. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends” or “continue,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Forward-looking statements are subject to numerous risks, uncertainties, and conditions, many of which are beyond the control of Celcuity. These include, but are not limited to, unforeseen delays in our clinical trials, our ability to obtain and maintain regulatory approvals to commercialize our products, and the market acceptance of such products, the development of therapies and tools competitive with our products, our ability to access capital upon favorable terms or at all, and those risks set forth in the Risk Factors section in Celcuity’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 31, 2025. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Celcuity undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.

View source version of release on GlobeNewswire.com

Contacts: 

Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com 
Vicky Hahne, vhahne@celcuity.com 
(763) 392-0123 

ICR Healthcare
Patti Bank, patti.bank@icrhealthcare.com
(415) 513-1284

Celcuity Inc.
Balance Sheets
 
 December 31, 2024 December 31, 2023
    
Assets    
Current Assets:    
Cash and cash equivalents$22,514,823 $30,662,774
Investments 212,588,960  149,919,974
Other current assets 9,467,247  10,007,849
Total current assets  244,571,030  190,590,597
    
Property and equipment, net 336,515  228,782
Operating lease right-of-use assets 215,502  400,019
Total Assets $ 245,123,047  $ 191,219,398
    
Liabilities and Stockholders’ Equity:    
Current Liabilities:    
Accounts payable$9,366,007 $5,076,699
Operating lease liabilities 171,952  184,950
Accrued expenses 22,184,948  8,927,094
Total current liabilities  31,722,907  14,188,743
Operating lease liabilities 53,969  225,922
Note payable, non-current 97,727,136  37,035,411
Total Liabilities  129,504,012  51,450,076
Total Stockholders’ Equity  115,619,035  139,769,322
Total Liabilities and Stockholders’ Equity $ 245,123,047  $ 191,219,398
    

Celcuity Inc.  
Statements of Operations  
   
   
 Three Months Ended December 31,
 Twelve Months Ended December 31, 
  2024   2023   2024   2023 
        
Operating expenses:        
        
Research and development$33,471,213  $18,081,194  $104,203,230  $60,594,005 
General and administrative 2,958,918   1,648,079   9,063,721   5,636,326 
Total operating expenses 36,430,131   19,729,273   113,266,951   66,230,331 
Loss from operations (36,430,131)   (19,729,273)   (113,266,951)   (66,230,331) 
        
Other (expense) income       
Interest expense (3,275,161)   (1,397,247)   (10,280,445)   (5,326,387) 
Interest income 3,052,251   2,278,048   11,768,291   7,777,602 
Other (expense) income, net (222,910)   880,801   1,487,846   2,451,215 
Net loss before income taxes   (36,653,041)    (18,848,472)    (111,779,105)    (63,779,116) 
Income tax benefits –   –   –   – 
Net loss $ (36,653,041)  $ (18,848,472)  $ (111,779,105)  $ (63,779,116) 
        
Net loss per share, basic and diluted$(0.85)  $(0.65)  $(2.83)  $(2.69) 
        
Weighted average common shares outstanding, basic and diluted 42,873,934   28,900,075   39,449,393   23,679,472 


Cautionary Statement Regarding Non-GAAP Financial Measures

This press release contains references to non-GAAP adjusted net loss and non-GAAP adjusted net loss per share. Management believes these non-GAAP financial measures are useful supplemental measures for planning, monitoring, and evaluating operational performance as they exclude stock-based compensation expense, non-cash interest expense, and non-cash interest income from net loss and net loss per share. Management excludes these items because they do not impact Celcuity’s cash position, which management believes better enables Celcuity to focus on cash used in operations. However, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share are not recognized measures under GAAP and do not have a standardized meaning prescribed by GAAP. As a result, management’s method of calculating non-GAAP adjusted net loss and non-GAAP adjusted net loss per share may differ materially from the method used by other companies. Therefore, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share may not be comparable to similarly titled measures presented by other companies. Investors are cautioned that non-GAAP adjusted net loss and non-GAAP adjusted net loss per share should not be construed as alternatives to net loss, net loss per share or other statements of operations data (which are determined in accordance with GAAP) as an indicator of Celcuity’s performance or as a measure of liquidity and cash flows.

Celcuity Inc.
Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and
GAAP Net Loss Per Share to Non-GAAP Adjusted Net Loss Per Share
 
 Three Months Ended December 31, Years Ended
  2024   2023   2024   2023 
        
GAAP net loss$(36,653,041)  $(18,848,472)  $(111,779,105)  $(63,779,116) 
Adjustments:       
Stock-based compensation       
Research and development (1) 1,403,877   745,629   4,404,518   2,700,318 
General and administrative (2) 911,404   496,904   2,583,823   2,201,116 
Non-cash interest expense (3) 803,222   528,637   2,694,361   2,052,336 
Non-cash interest income (4) 1,262,841   (554,126)   150,421   (993,457) 
Non-GAAP adjusted net loss$ (32,271,697)  $ (17,631,428)  $ (101,945,982)  $ (57,818,803) 
        
GAAP net loss per share – basic and diluted$(0.85)  $(0.65)  $(2.83)  $(2.69) 
Adjustment to net loss (as detailed above) 0.10   0.04   0.25   0.25 
Non-GAAP adjusted net loss per share$ (0.75)  $ (0.61)  $ (2.58)  $ (2.44) 
        
Weighted average common shares outstanding, basic and diluted 42,873,934   28,900,075   39,449,393   23,679,472 

(1) To reflect a non-cash charge to operating expense for Research and Development stock-based compensation.
(2) To reflect a non-cash charge to operating expense for General and Administrative stock-based compensation.
(3) To reflect a non-cash charge to other expense for amortization of debt issuance and discount costs and PIK interest related to the issuance of a note payable.
(4) To reflect a non-cash adjustment to other income for accretion on investments.

  • Author
  • Recent Posts
GlobeNewswire
GlobeNewswire
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
GlobeNewswire
Latest posts by GlobeNewswire (see all)
  • DV DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages DoubleVerify Holdings, Inc. Investors to Secure Counsel Before Important July 21 Deadline in Securities Class Action – DV - July 19, 2025
  • Arctic Pablo Coin Launches Weekly Myth-Themed Presale Structure with $0.0005 Entry Price and Token Burn Mechanism - July 19, 2025
  • RCAT DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Red Cat Holdings, Inc. Investors to Secure Counsel Before Important July 22 Deadline in Securities Class Action – RCAT - July 19, 2025
ADVERTISEMENTS
americas favorite vodka

Related Posts

DV DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages DoubleVerify Holdings, Inc. Investors to Secure Counsel Before Important July 21 Deadline in Securities Class Action – DV

by GlobeNewswire
July 19, 2025
0

NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers...

Arctic Pablo Coin Launches Weekly Myth-Themed Presale Structure with $0.0005 Entry Price and Token Burn Mechanism

by GlobeNewswire
July 19, 2025
0

LONDON, July 19, 2025 (GLOBE NEWSWIRE) -- Arctic Pablo Coin (APC), a blockchain-based meme project with a narrative-driven structure, today...

RCAT DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Red Cat Holdings, Inc. Investors to Secure Counsel Before Important July 22 Deadline in Securities Class Action – RCAT

by GlobeNewswire
July 19, 2025
0

NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of...

OGN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important July 22 Deadline in Securities Class Action – OGN

by GlobeNewswire
July 19, 2025
0

NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of...

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages iRobot Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – IRBT

by GlobeNewswire
July 19, 2025
0

NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of...

FORTREA ALERT: Bragar Eagel & Squire, P.C. Urges Investors in Fortrea Holdings (FTRE) to Inquire About Their Rights in Class Action Lawsuit

by GlobeNewswire
July 19, 2025
0

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Fortrea Holdings (FTRE) To Contact Him Directly...

Next Post

INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results

Please login to join discussion
ADVERTISEMENTS

Latest Posts

  • DV DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages DoubleVerify Holdings, Inc. Investors to Secure Counsel Before Important July 21 Deadline in Securities Class Action – DV July 19, 2025
  • Arctic Pablo Coin Launches Weekly Myth-Themed Presale Structure with $0.0005 Entry Price and Token Burn Mechanism July 19, 2025
  • RCAT DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Red Cat Holdings, Inc. Investors to Secure Counsel Before Important July 22 Deadline in Securities Class Action – RCAT July 19, 2025
  • OGN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important July 22 Deadline in Securities Class Action – OGN July 19, 2025
  • ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages iRobot Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – IRBT July 19, 2025
  • About Us
  • Advertise
  • Careers
  • Contact
Privacy Policy / Terms and Conditions

© 2024 ForexTV.com

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Cookie Policy
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
No Result
View All Result
  • News
    • Top Corporate News
    • Lifestyle
    • Technology
    • Financial Markets News
  • Small Business
    • Digital Marketing Blog
    • Small Business Best Practices
    • Small Business Strategy
      • Sales Strategies
      • Marketing Strategies
  • Business Finance
    • Small Business-Lending Trends
    • Debt Service Coverage Ratio (DSCR)
    • Business Credit
      • Business Credit Blog
      • Business Loans
      • Merchant Cash Advances
      • Business Line of Credit
      • What is Alternative Business Lending?
    • Resources
      • Debt Service Coverage Ratio (DSCR) Calculator
  • Currency Focus
    • Crypto Focus
      • Bitcoin (BTC)
      • Ethereum (ETH)
      • Tether
      • BNB
      • Cardano (Ada)
      • Ripple (XRP)
      • Solana (SOL)
      • Dogecoin (DOGE)
      • Polkadot (DOT)
      • Tron (TRX)
      • Shiba Inu (SHIB)
      • Litecoin (LTC)
    • EURO (EUR)
    • Japanese Yen (JPY)
    • Great British Pound (GBP)
    • Swiss Franc (CHF)
    • New Zealand Dollar (NZD)
    • Canadian Dollar (CAD)
    • Australian Dollar (AUD)
  • Resources
    • Economic Calendar
    • Trader Education
      • Candlestick Pattern Intro
    • Live Forex Rates/Charts
      • Live Rates
      • Live Charts
    • Forex Trader Tools
      • Pivot Point Calculator
      • Currency Converter
      • Global Statistic Resources
    • Trading Terms
      • Forex Glossary
      • Glossary of Retirement Industry Terms
    • CPI Tools
      • CPI Inflation Calculator
      • CPI Average Price Calculator
  • Marketing Services
    • Digital Marketing Services
    • Digital Marketing Consulting
    • Search Engine Optimization (SEO)
    • Online Content Marketing
    • Digital Marketing Blog
    • Inbound Marketing Services
    • Email Marketing
    • Digital Marketing Rates

© 2024 ForexTV.com